Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $4.4 million.

  • Guardian Pharmacy Services' Share-based Compensation fell 9643.99% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year decrease of 8458.6%. This contributed to the annual value of $131.5 million for FY2024, which is 225911.33% up from last year.
  • As of Q3 2025, Guardian Pharmacy Services' Share-based Compensation stood at $4.4 million, which was down 9643.99% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Guardian Pharmacy Services' Share-based Compensation peaked at $122.4 million during Q3 2024, and registered a low of -$22.7 million during Q4 2023.
  • Over the past 3 years, Guardian Pharmacy Services' median Share-based Compensation value was $4.2 million (recorded in 2025), while the average stood at $15.2 million.
  • Over the last 5 years, Guardian Pharmacy Services' Share-based Compensation had its largest YoY gain of 173492.65% in 2025, and its largest YoY loss of 9643.99% in 2025.
  • Guardian Pharmacy Services' Share-based Compensation (Quarter) stood at -$22.7 million in 2023, then soared by 115.23% to $3.5 million in 2024, then increased by 25.86% to $4.4 million in 2025.
  • Its Share-based Compensation stands at $4.4 million for Q3 2025, versus $4.4 million for Q2 2025 and $4.0 million for Q1 2025.